Newsletter | 01 July 2004 Access News 10, Focus on AIDS Treatment, July 2004 INTELLECTUAL PROPERTY AND TRADE In this edition of AccessNews, the challenges of AIDS treatment is focused on, as well as the importance of patient activism to expand treatment, MSF AIDS programs FDCs and Africa starting to ACT against malaria. Read, watch, share Filter by - Any -BlogEventsFeature storyInterviewIssue briefLetterNewsletterOpinion articlePhoto storyPress releaseReportReport seriesResearch articleSpeechStatementTechnical briefVideo Press release Press release | 30 March 2026 HIV/AIDS Gilead refuses to sell groundbreaking HIV prevention drug to MSF Photo credit: Jan-Joseph Stok Press release Press release | 26 September 2025 HIV/AIDS MSF Supports $40 PrEP Access by 2027, Demands Broader Reach and more Ambition to End HIV Epidemic 3 min Technical brief | 03 July 2025 HIV/AIDS Intellectual property and trade Gilead’s Voluntary License on Lenacapavir: Key Limitations of the License and Recommendations to Improve Access Copyright: Stefan Heunis Press release Press release | 15 May 2025 HIV/AIDS Tuberculosis South AfricaUnited States of America US funding cuts threaten 39 research sites in South Africa, putting scientific advancements and hard-won progress against TB and HIV at risk 5 min Technical brief | 04 September 2024 HIV/AIDS Hidden Costs: GeneXpert Tests and Danaher’s Delayed Audit Research article | 16 August 2024 HIV/AIDS Lancet HIV: The long wait for long-acting HIV prevention and treatment formulations Research article | 14 August 2024 HIV/AIDS Lancet Global Health: Paving the way for affordable and equitable liposomal amphotericin B access worldwide Newsletter Newsletter | 02 August 2024 HIV/AIDS Why we went to the International AIDS Conference this year...and what we did! Load More
Press release Press release | 30 March 2026 HIV/AIDS Gilead refuses to sell groundbreaking HIV prevention drug to MSF
Photo credit: Jan-Joseph Stok Press release Press release | 26 September 2025 HIV/AIDS MSF Supports $40 PrEP Access by 2027, Demands Broader Reach and more Ambition to End HIV Epidemic 3 min
Technical brief | 03 July 2025 HIV/AIDS Intellectual property and trade Gilead’s Voluntary License on Lenacapavir: Key Limitations of the License and Recommendations to Improve Access
Copyright: Stefan Heunis Press release Press release | 15 May 2025 HIV/AIDS Tuberculosis South AfricaUnited States of America US funding cuts threaten 39 research sites in South Africa, putting scientific advancements and hard-won progress against TB and HIV at risk 5 min
Technical brief | 04 September 2024 HIV/AIDS Hidden Costs: GeneXpert Tests and Danaher’s Delayed Audit
Research article | 16 August 2024 HIV/AIDS Lancet HIV: The long wait for long-acting HIV prevention and treatment formulations
Research article | 14 August 2024 HIV/AIDS Lancet Global Health: Paving the way for affordable and equitable liposomal amphotericin B access worldwide
Newsletter Newsletter | 02 August 2024 HIV/AIDS Why we went to the International AIDS Conference this year...and what we did!
